Condition: Malignant Pleural Effusion · Malignant Ascites · Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.
This description comes directly from the study's public registry record.
Patrick Wagner, MD · 412-359-3731 · patrick.wagner@ahn.org
AHN Clinical Trial Contact · 412-359-3731 · clinicaltrials@ahn.org
Always discuss trial participation with your own doctor first.
| Allegheny Health Network Cancer Institute | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06016179